Velo3D Q4 revenue $29-30M beats guidance; reports new material weakness

Velo3D, Inc.

2022-FY EPS reported $0.05 revenue$80,757,000

Q4 2022 revenue $29-30M (exceeded prior guidance); FY2022 revenue $80-81M.
Q4 gross margin 5-6%; FY2022 gross margin 3-4%.
Operating loss continues for both Q4 and FY2022.
Cash and investments ~$81M as of Dec 31, 2022.
Discloses additional material weakness in internal controls over inventory existence and cost of revenue completeness.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Velo3D, Inc. reported fiscal year ended December 31, 2022 results: revenue in the range of $80 million to $81 million.

Period: fiscal year ended December 31, 2022
Revenue: in the range of $80 million to $81 million
Result: preliminary results

Exact text from the filing

For fiscal year ended December 31, 2022, revenue will be in the range of $80 million to $81 million and gross margin will be in the range of 3.0 percent to 4.0 percent.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Velo3D, Inc. reported the fourth quarter ended December 31, 2022 results: revenue in the range of $29 million to $30 million.

Period: the fourth quarter ended December 31, 2022
Revenue: in the range of $29 million to $30 million
Result: preliminary results

Exact text from the filing

the company preliminarily estimates that: • For the fourth quarter ended December 31,2022, revenue will exceed the company’s previous guidance and be in the range of $29 million to $30 million.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Velo3D, Inc. filing history →

Source: SEC EDGAR

accession 0001825079-23-000001

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.